certificate of analysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-17. Numbers and descriptions here follow the published literature rather than marketing material.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
== Legal status == Difenoxin is a Schedule I drug by itself in the US; the combination with atropine is in the less-restrictive category Schedule IV on account of the adulterant (the practice of making opioids more easily available by including an abuse-deterring adulterating agent is standard practice in the United States). Pure difenoxin, in Schedule I, has a quota of 50 grammes, and an ACSCN of 9168. The combination of difenoxin and atropine, in Schedule IV, has the DEA ACSCN of 9167 and being in Schedule IV is not assigned an aggregate annual manufacturing quota.
Although progesterone does not have significant AR-mediated androgenic or antiandrogenic activity, it is a precursor and intermediate, albeit distant, in the biosynthesis of androgens from cholesterol. For this reason, there has been some speculation that exogenous progesterone could be transformed into androgens by certain tissues that express the requisite enzymes. Progesterone is converted by 17α-hydroxylase into 17α-hydroxyprogesterone; 17α-hydroxyprogesterone is converted by 17,20-lyase into androstenedione; and androstenedione is converted by 17β-hydroxysteroid dehydrogenases into testosterone. CYP17A1, the cytochrome P450 gene that encodes 17α-hydroxylase and 17,20-lyase, is expressed mainly in the gonads (ovaries and testes) and the adrenal glands. However, while it is theoretically possible that progesterone could be transformed in the body into androgens, no androgenic effects have been observed in animal studies. In addition, clinical studies, in which women were treated with 100 to 300 mg/day oral progesterone, have found no or only a small increase in levels of 17α-hydroxyprogesterone, and no change in androgen levels, including of dehydroepiandrosterone, androstenedione, and testosterone. In these studies, levels of estradiol and cortisol, which progesterone is also a precursor of, did not change either, although levels of 11-deoxycorticosterone increased significantly.
== Scientific implications and other uses == SPINA-Beta significantly correlates with biomarkers for the allostatic load. The direction is positive, i. e., higher allostatic load is associated with higher beta cell function. This is probably due to increased beta cell mass as a result of dynamical compensation. Together with the reconstructed insulin receptor gain (SPINA-GR), SPINA-GBeta provides the foundation for the definition of a fasting based disposition index of insulin-glucose homeostasis (SPINA-DI). In combination with SPINA-GR and whole-exome sequencing, calculating SPINA-GBeta helped to identify a new form of monogenetic diabetes (MODY) that is characterised by primary insulin resistance and results from a missense variant of the type 2 ryanodine receptor (RyR2) gene (p.N2291D).
Biomass is material produced by the growth of microorganisms, plants or animals. Beyond this general definition, there are differences in how the term is used and applied depending on industry or subject-matter norms. For example, it may be more narrowly defined as just plant matter, or as a combination of plant and animal matter.
Homocysteine levels typically are higher in men than women, and increase with age. Common levels in Western populations are 10 to 12 μmol/L, and levels of 20 μmol/L are found in populations with low B-vitamin intakes or in the elderly (e.g., Rotterdam, Framingham). It is decreased with methyl folate trapping, where it is accompanied by decreased methylmalonic acid, increased folate, and a decrease in formiminoglutamic acid. This is the opposite of MTHFR C677T mutations, which result in an increase in homocysteine.
Sources: en.wikipedia.org
In February 1968, ruling on Madzimbamuto's appeal, Beadle concluded that the Smith administration would be recognised by the local judiciary as the de facto government by virtue of its "effective control over the state's territory", but that de jure recognition would be withheld as this was not "firmly established". Madzimbamuto applied for the right to appeal to the British Privy Council; the Rhodesian Appellate Division promptly ruled that he had no right to do so, but the Privy Council considered his case anyway. In late February 1968, considering the fate of James Dhlamini, Victor Mlambo and Duly Shadreck, three black Rhodesians convicted of murder and terrorist offences before UDI, Beadle ruled that Salisbury retained its pre-UDI powers regarding executions and could carry out death sentences. Whitehall announced on 1 March that at the request of the UK government, the Queen had exercised the royal prerogative of mercy and commuted the three death sentences to life imprisonment. Dhlamini and the others applied for a permanent stay of execution on this basis. At the hearing for Dhlamini and Mlambo on 4 March 1968, Beadle argued that he saw the statement from London as a decision by the UK government and not the Queen herself, and that in any case the 1961 constitution had transferred the prerogative of mercy from Britain to the Rhodesian Executive Council. "The present government is the fully de facto government and as such is the only power that can exercise the prerogative", he concluded.
Brown adipose tissue activation improves glucose homeostasis and insulin sensitivity in humans suggesting that anyone with impaired insulin function might benefit from BAT activation; however, there is broader application given research showing even mildly elevated blood glucose in healthy non-diabetic humans is associated with damage over time of many organs such as eyes, tendons, endothelial/cardiovascular system and brain, and results in higher levels of damaging advanced glycation end products. Brown adipose tissue activation may play an important role in bone health and bone density. Brown adipose tissue activation through cold exposure increases adiponectin levels, just two hours of cold exposure resulted in a 70% increase in circulating adiponectin in adult men. Centenarians (both men and women) and their offspring have been found to have genetics that boost adiponectin, and they have higher circulating adiponectin, suggesting a link between longevity and adiponectin production. In addition, high concentrations of plasma adiponectin in centenarians was associated with favorable metabolic indicators, and with lower levels of C-reactive protein and E-selectin. Cold exposure increases circulating irisin. Irisin improves insulin sensitivity, increases bone quality and quantity, is involved in the building of lean muscle mass, and helps reduce obesity by converting white fat to brown fat, providing many of the same benefits of exercise.
Otto Knut Olof Folin (April 4, 1867 – October 25, 1934) was a Swedish-born American chemist who is best known for his groundbreaking work at Harvard University on practical micromethods for the determination of the constituents of protein-free blood filtrates and the discovery of creatine phosphate in muscles.
Luigi Tripepi (7 January 1903 – 29 December 1906) Sebastiano Martinelli (8 February 1909 – 4 July 1918) Scipione Tecchi (8 November 1914 – 7 February 1915) Antonio Vico (11 February 1915 – 25 February 1929) Camillo Laurenti (12 March 1929 – 6 September 1938) Carlo Salotti (14 September 1938 – 24 October 1947) Clemente Micara (11 November 1950 – 17 January 1953) Gaetano Cicognani (7 December 1953 – 18 November 1954) Arcadio Larraona Saralegui (12 February 1962 – 9 January 1968) Benno Gut (29 June 1967 – 7 May 1969)
Sources: en.wikipedia.org
Demon Copperhead is a 2022 novel by Barbara Kingsolver. It was a co-recipient of the 2023 Pulitzer Prize for Fiction, and won the 2023 Women's Prize for Fiction. Kingsolver was inspired by the Charles Dickens novel David Copperfield. While Kingsolver's novel is similarly about a boy who experiences poverty, Demon Copperhead is set in Appalachia and explores contemporary issues. The book touches on themes of the social and economic stratification in Appalachia, child poverty in rural America, and drug addiction with a focus on the opioid crisis.
An additional 35 primordial nuclides (to a total of 286 primordial nuclides), are radioactive with known half-lives, but have half-lives longer than 100 million years, allowing them to exist from the beginning of the Solar System. See list of nuclides for details. All the known stable nuclides occur naturally on Earth; the other naturally occurring nuclides are radioactive but occur on Earth due to their relatively long half-lives, or else due to other means of ongoing natural production. These include the afore-mentioned cosmogenic nuclides, the nucleogenic nuclides, and any radiogenic nuclides formed by ongoing decay of a primordial radioactive nuclide, such as radon and radium from uranium. An additional ~3000 radioactive nuclides not found in nature have been created in nuclear reactors and in particle accelerators. Many short-lived nuclides not found naturally on Earth have also been observed by spectroscopic analysis, being naturally created in stars or supernovae. An example is aluminium-26, which is not naturally found on Earth but is found in abundance on an astronomical scale. The tabulated atomic masses of elements are averages that account for the presence of multiple isotopes with different masses. Before the discovery of isotopes, empirically determined noninteger values of relative atomic mass confounded scientists. For example, a sample of chlorine contains 75.8% chlorine-35 and 24.2% chlorine-37, giving an average atomic mass of 35.5 daltons.
=== Names === Cyproheptadine is the generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française. The drug's DCITTooltip Denominazione Comune Italiana is ciproeptadina, while its BANMTooltip British Approved Name is cyproheptadine hydrochloride (as the hydrochloride salt) and its JANTooltip Japanese Accepted Name is cyproheptadine hydrochloride hydrate (as the hydrochloride hydrate form). Synonyms of cyproheptadine include Fl-5967, HSp-1229, Glutodina, Axoprol, and Dihexazin. The drug is sold under many brand names, but its major brand names are Periactin and to a lesser extent Peritol.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.